Want to see CCEL full AI Analyst Report?
CCEL Stock Chart & Stats
$3.46
-$0.04(-1.14%)
At close: 4:00 PM EDT
$3.46
-$0.04(-1.14%)
Day’s Range― - ―
52-Week Range$2.72 - $5.01
Previous Close$3.46
Volume3.00K
Average Volume (3M)4.07K
Market Cap
$33.70M
Enterprise Value$32.94
Total Cash (Recent Filing)$3.16M
Total Debt (Recent Filing)$8.96M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Oct 09, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding8,062,650
10 Day Avg. Volume4,683
30 Day Avg. Volume4,066
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$30.04M
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow provide internal funding for operations and reduce dependence on external capital. This is a meaningful strength because cash generation remains positive despite reported losses, although its durability depends on stabilizing revenue.
Strong Gross MarginA high gross margin indicates that Cryo-Cell’s processing and storage services retain substantial value after direct costs. If customer retention and acquisition improve, this margin structure could support operating leverage and eventual profitability.
Low Reported DebtThe relatively small debt balance limits interest and refinancing pressure compared with a highly leveraged structure. This offers some financial flexibility for a recurring-storage business, though the benefit is constrained by the company’s deeply negative equity position.
Bears Say
Sharp Revenue ContractionA sustained top-line decline would weaken the customer base and reduce the pool of new upfront enrollments that can feed future storage revenue. It also limits operating leverage, making it harder for the company to absorb fixed laboratory, marketing, and facility costs.
Recurring UnprofitabilityLosses indicate that the company’s strong gross margin is currently insufficient to cover operating and other costs. Continued earnings volatility can restrict reinvestment, weaken resilience during periods of lower births or demand, and make positive cash flow harder to sustain.
Deeply Negative EquityNegative equity signals a strained capital structure and reduces the company’s financial cushion if operating results deteriorate. It can constrain access to financing, complicate leverage assessment, and increase dependence on continued cash generation despite ongoing losses.
Cryo-Cell International News
CCEL FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was $2.72 and its highest was $5.00 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Cryo-Cell International Inc’s market cap is $33.70M.
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Oct 09, 2026 which is in 48 days.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Jul 15, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0 by $0.07.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc pays a Quarterly dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Cryo-Cell International Inc dividends here
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is 0.03.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,062,650 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of $0.07 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went down -2.657%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in CCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryo-Cell International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Cryo-Cell International Inc
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Technical Analysis
Concord Medical Services
―
Strata Critical Medical
―
NewGenIvf Group
―
Basel Medical Group Ltd
―
20/20 Biolabs, Inc.
―
Ownership Overview
35.76% Insiders
2.57% Mutual Funds
2.05% Other Institutional Investors
57.89% Public Companies and
Individual Investors